KURA
insider transactionsKura Oncology, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-188.7K
0 buy · 188.7K sell
Net value · 365d
-$4.8M
$0 in · $4.8M out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
30
0 buy · 188.7K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
35.0K sh
Own New
-
Grant·A
Director
$0
35.0K sh
Own New
-
Grant·A
Director
$0
35.0K sh
Own New
-
Grant·A
Director
$0
35.0K sh
Own New
-
Grant·A
Director
$0
35.0K sh
Own New
-
Grant·A
Director
$0
35.0K sh
Own New
-
Grant·A
Director
$0
35.0K sh
Own New
-
Sell·S
Chief Commercial Officer · 10b5-1
$110.0K
10.0K sh · $11.00
Own -5%
-
Sell·S
Chief Commercial Officer · 10b5-1
$3.1K
339 sh · $9.21
Own -0%
-
Sell·S
Chief Operating Officer · 10b5-1
$20.5K
2.3K sh · $9.08
Own -1%
-
Exercise·M
CHIEF MEDICAL OFFICER · 10b5-1
$0
5.0K sh
Own +4%
-
Sell·S
CHIEF MEDICAL OFFICER · 10b5-1
$9.2K
223 sh · $41.21
Own -1%
-
Sell·S
CHIEF MEDICAL OFFICER · 10b5-1
$52.4K
1.3K sh · $40.25
Own -5%
-
Sell·S
CHIEF MEDICAL OFFICER · 10b5-1
$137.4K
3.5K sh · $39.53
Own -12%
-
Exercise·M
CHIEF MEDICAL OFFICER · 10b5-1
$12.4K
5.0K sh · $2.48
Own +20%
-
Sell·S
Chief Legal Officer · 10b5-1
$21.2K
2.3K sh · $9.38
Own -1%
-
Exercise·M
CHIEF MEDICAL OFFICER · 10b5-1
$0
5.0K sh
Own +4%
-
Sell·S
CHIEF MEDICAL OFFICER · 10b5-1
$117.3K
2.4K sh · $48.06
Own -9%
-
Sell·S
CHIEF MEDICAL OFFICER · 10b5-1
$114.6K
2.4K sh · $47.39
Own -8%
-
Sell·S
CHIEF MEDICAL OFFICER · 10b5-1
$6.4K
140 sh · $45.81
Own -0%
-
Exercise·M
CHIEF MEDICAL OFFICER · 10b5-1
$12.4K
5.0K sh · $2.48
Own +20%
-
Exercise·M
CHIEF MEDICAL OFFICER · 10b5-1
$0
40.0K sh
Own +42%
-
Sell·S
CHIEF MEDICAL OFFICER · 10b5-1
$1.4M
40.0K sh · $35.10
Own -62%
-
Exercise·M
CHIEF MEDICAL OFFICER · 10b5-1
$99.2K
40.0K sh · $2.48
Own +160%
-
Exercise·M
President and CEO
$0
6.1K sh
Own New
-
Exercise·M
President and CEO
$37.5K
6.1K sh · $6.15
Own +1%
-
Exercise·M
Director
$0
10.0K sh
Own New
-
Exercise·M
Director
$31.2K
10.0K sh · $3.12
Own New
-
Exercise·M
CHIEF MEDICAL OFFICER · 10b5-1
$0
5.0K sh
Own +3%
-
Sell·S
CHIEF MEDICAL OFFICER · 10b5-1
$138.8K
5.0K sh · $27.76
Own -17%
-
Exercise·M
CHIEF MEDICAL OFFICER · 10b5-1
$12.4K
5.0K sh · $2.48
Own +20%
-
Exercise·M
CHIEF MEDICAL OFFICER · 10b5-1
$0
10.1K sh
Own +6%
-
Sell·S
CHIEF MEDICAL OFFICER · 10b5-1
$305.8K
10.1K sh · $30.19
Own -29%
-
Exercise·M
CHIEF MEDICAL OFFICER · 10b5-1
$25.1K
10.1K sh · $2.48
Own +41%
-
Exercise·M
CHIEF MEDICAL OFFICER · 10b5-1
$0
29.9K sh
Own +18%
-
Sell·S
CHIEF MEDICAL OFFICER · 10b5-1
$896.8K
29.9K sh · $30.02
Own -54%
-
Exercise·M
CHIEF MEDICAL OFFICER · 10b5-1
$74.1K
29.9K sh · $2.48
Own +119%
-
Exercise·M
CHIEF MEDICAL OFFICER · 10b5-1
$0
45.0K sh
Own +26%
-
Sell·S
CHIEF MEDICAL OFFICER · 10b5-1
$1.2M
45.0K sh · $26.17
Own -64%
-
Exercise·M
CHIEF MEDICAL OFFICER · 10b5-1
$111.6K
45.0K sh · $2.48
Own +180%
-
Grant·A
CHIEF MEDICAL OFFICER
$0
150.0K sh
Own New
-
Grant·A
CHIEF MEDICAL OFFICER
$0
25.0K sh
Own New
-
Sell·S
Chief Commercial Officer
$13.3K
1.6K sh · $8.46
Own -1%
-
Sell·S
Chief Commercial Officer
$41.0K
4.8K sh · $8.46
Own -3%
-
Sell·S
Chief Medical Officer
$11.3K
1.3K sh · $8.46
Own -0%
-
Sell·S
Chief Medical Officer
$8.0K
951 sh · $8.46
Own -0%
-
Sell·S
Chief Medical Officer
$18.9K
2.2K sh · $8.46
Own -1%
-
Sell·S
Chief Medical Officer
$30.9K
3.7K sh · $8.46
Own -1%
-
Sell·S
Chief Operating Officer
$15.3K
1.8K sh · $8.46
Own -1%
-
Sell·S
SVP, Finance & Accounting
$7.5K
881 sh · $8.46
Own -1%
-
Sell·S
SVP, Finance & Accounting
$5.9K
695 sh · $8.46
Own -0%
-
Sell·S
SVP, Finance & Accounting
$9.4K
1.1K sh · $8.46
Own -1%
-
Sell·S
SVP, Finance & Accounting
$18.8K
2.2K sh · $8.46
Own -1%
-
Sell·S
Chief Scientific Officer
$11.1K
1.3K sh · $8.46
Own -4%
-
Sell·S
Chief Legal Officer
$40.4K
4.8K sh · $8.46
Own -2%
-
Sell·S
Chief Legal Officer
$19.8K
2.3K sh · $8.46
Own -1%
-
Sell·S
Chief Legal Officer
$34.7K
4.1K sh · $8.46
Own -2%
-
Grant·A
President and CEO
$0
1.1M sh
Own New
-
Grant·A
Chief Medical Officer
$0
100.0K sh
Own New
-
Grant·A
Chief Medical Officer
$0
50.0K sh
Own +22%
-
Grant·A
Chief Commercial Officer
$0
100.0K sh
Own New
-
Grant·A
Chief Commercial Officer
$0
50.0K sh
Own +36%
-
Grant·A
Chief Operating Officer
$0
100.0K sh
Own New
-
Grant·A
Chief Operating Officer
$0
50.0K sh
Own +47%
-
Grant·A
SVP, Finance & Accounting
$0
42.5K sh
Own New
-
Grant·A
SVP, Finance & Accounting
$0
21.2K sh
Own +16%
-
Grant·A
Chief Scientific Officer
$0
185.0K sh
Own New
-
Grant·A
Chief Legal Officer
$0
100.0K sh
Own New
-
Grant·A
Chief Legal Officer
$0
50.0K sh
Own +27%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 4, 2026 | Diane L. Parks | Grant A | 35.0K | $0 |
| Jun 4, 2026 | Michael Vasconcelles | Grant A | 35.0K | $0 |
| Jun 4, 2026 | Carol Schafer | Grant A | 35.0K | $0 |
| Jun 4, 2026 | Mary T Szela | Grant A | 35.0K | $0 |
| Jun 4, 2026 | Thomas Malley | Grant A | 35.0K | $0 |
| Jun 4, 2026 | Faheem Hasnain | Grant A | 35.0K | $0 |
| Jun 4, 2026 | Helen Louise Collins | Grant A | 35.0K | $0 |
| May 21, 2026 | Brian T. Powl 10b5-1 | Sell S | 10.0K | $110.0K |
| May 19, 2026 | Brian T. Powl 10b5-1 | Sell S | 339 | $3.1K |
| May 19, 2026 | Kathleen Ford 10b5-1 | Sell S | 2.3K | $20.5K |
| May 18, 2026 | Helen Louise Collins 10b5-1 | Exercise M | 5.0K | $0 |
| May 18, 2026 | Helen Louise Collins 10b5-1 | Sell S | 223 | $9.2K |
| May 18, 2026 | Helen Louise Collins 10b5-1 | Sell S | 1.3K | $52.4K |
| May 18, 2026 | Helen Louise Collins 10b5-1 | Sell S | 3.5K | $137.4K |
| May 18, 2026 | Helen Louise Collins 10b5-1 | Exercise M | 5.0K | $12.4K |
| May 18, 2026 | Teresa Brophy Bair 10b5-1 | Sell S | 2.3K | $21.2K |
| Apr 17, 2026 | Helen Louise Collins 10b5-1 | Exercise M | 5.0K | $0 |
| Apr 17, 2026 | Helen Louise Collins 10b5-1 | Sell S | 2.4K | $117.3K |
| Apr 17, 2026 | Helen Louise Collins 10b5-1 | Sell S | 2.4K | $114.6K |
| Apr 17, 2026 | Helen Louise Collins 10b5-1 | Sell S | 140 | $6.4K |
| Apr 17, 2026 | Helen Louise Collins 10b5-1 | Exercise M | 5.0K | $12.4K |
| Mar 25, 2026 | Helen Louise Collins 10b5-1 | Exercise M | 40.0K | $0 |
| Mar 25, 2026 | Helen Louise Collins 10b5-1 | Sell S | 40.0K | $1.4M |
| Mar 25, 2026 | Helen Louise Collins 10b5-1 | Exercise M | 40.0K | $99.2K |
| Mar 23, 2026 | Troy Edward Wilson KEY | Exercise M | 6.1K | $0 |
| Mar 23, 2026 | Troy Edward Wilson KEY | Exercise M | 6.1K | $37.5K |
| Mar 18, 2026 | Thomas Malley | Exercise M | 10.0K | $0 |
| Mar 18, 2026 | Thomas Malley | Exercise M | 10.0K | $31.2K |
| Mar 17, 2026 | Helen Louise Collins 10b5-1 | Exercise M | 5.0K | $0 |
| Mar 17, 2026 | Helen Louise Collins 10b5-1 | Sell S | 5.0K | $138.8K |
| Mar 17, 2026 | Helen Louise Collins 10b5-1 | Exercise M | 5.0K | $12.4K |
| Mar 10, 2026 | Helen Louise Collins 10b5-1 | Exercise M | 10.1K | $0 |
| Mar 10, 2026 | Helen Louise Collins 10b5-1 | Sell S | 10.1K | $305.8K |
| Mar 10, 2026 | Helen Louise Collins 10b5-1 | Exercise M | 10.1K | $25.1K |
| Mar 9, 2026 | Helen Louise Collins 10b5-1 | Exercise M | 29.9K | $0 |
| Mar 9, 2026 | Helen Louise Collins 10b5-1 | Sell S | 29.9K | $896.8K |
| Mar 9, 2026 | Helen Louise Collins 10b5-1 | Exercise M | 29.9K | $74.1K |
| Feb 17, 2026 | Helen Louise Collins 10b5-1 | Exercise M | 45.0K | $0 |
| Feb 17, 2026 | Helen Louise Collins 10b5-1 | Sell S | 45.0K | $1.2M |
| Feb 17, 2026 | Helen Louise Collins 10b5-1 | Exercise M | 45.0K | $111.6K |
| Feb 12, 2026 | Helen Louise Collins | Grant A | 150.0K | $0 |
| Feb 12, 2026 | Helen Louise Collins | Grant A | 25.0K | $0 |
| Jan 27, 2026 | Brian T. Powl | Sell S | 1.6K | $13.3K |
| Jan 27, 2026 | Brian T. Powl | Sell S | 4.8K | $41.0K |
| Jan 27, 2026 | Mollie Leoni | Sell S | 1.3K | $11.3K |
| Jan 27, 2026 | Mollie Leoni | Sell S | 951 | $8.0K |
| Jan 27, 2026 | Mollie Leoni | Sell S | 2.2K | $18.9K |
| Jan 27, 2026 | Mollie Leoni | Sell S | 3.7K | $30.9K |
| Jan 27, 2026 | Kathleen Ford | Sell S | 1.8K | $15.3K |
| Jan 27, 2026 | Thomas James Doyle | Sell S | 881 | $7.5K |
| Jan 27, 2026 | Thomas James Doyle | Sell S | 695 | $5.9K |
| Jan 27, 2026 | Thomas James Doyle | Sell S | 1.1K | $9.4K |
| Jan 27, 2026 | Thomas James Doyle | Sell S | 2.2K | $18.8K |
| Jan 27, 2026 | Francis Burrows | Sell S | 1.3K | $11.1K |
| Jan 27, 2026 | Teresa Brophy Bair | Sell S | 4.8K | $40.4K |
| Jan 27, 2026 | Teresa Brophy Bair | Sell S | 2.3K | $19.8K |
| Jan 27, 2026 | Teresa Brophy Bair | Sell S | 4.1K | $34.7K |
| Jan 2, 2026 | Troy Edward Wilson KEY | Grant A | 1.1M | $0 |
| Jan 2, 2026 | Mollie Leoni | Grant A | 100.0K | $0 |
| Jan 2, 2026 | Mollie Leoni | Grant A | 50.0K | $0 |
| Jan 2, 2026 | Brian T. Powl | Grant A | 100.0K | $0 |
| Jan 2, 2026 | Brian T. Powl | Grant A | 50.0K | $0 |
| Jan 2, 2026 | Kathleen Ford | Grant A | 100.0K | $0 |
| Jan 2, 2026 | Kathleen Ford | Grant A | 50.0K | $0 |
| Jan 2, 2026 | Thomas James Doyle | Grant A | 42.5K | $0 |
| Jan 2, 2026 | Thomas James Doyle | Grant A | 21.2K | $0 |
| Jan 2, 2026 | Francis Burrows | Grant A | 185.0K | $0 |
| Jan 2, 2026 | Teresa Brophy Bair | Grant A | 100.0K | $0 |
| Jan 2, 2026 | Teresa Brophy Bair | Grant A | 50.0K | $0 |
About KURA insider trading
This page tracks insider transactions for Kura Oncology, Inc. (KURA) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.